FOXBOROUGH, Mass.--(BUSINESS WIRE)--April 17, 2006--Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN: “Cyberkinetics”) announced that the Journal of Neuroscience published two studies conducted by research teams at Purdue University’s Center for Paralysis Research concerning technology licensed to Cyberkinetics. Together, the studies indicate that hydralazine, already approved for other uses by the FDA, and certain related compounds may prevent neural cell death by halting the toxic chemical process that normally occurs following an injury. Cyberkinetics Neurotechnology Systems, Inc. holds an exclusive, worldwide license to this technology.
